GWAS of composite biomarker score

Exploratory Score: 0.900 Price: $0.50 Alzheimer's disease human patients - East Asian cohort (K-ROAD) Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting PPP4R2, APOE in human patients - East Asian cohort (K-ROAD). Primary outcome: composite biomarker score

Description

Genome-wide association study of a composite score combining multiple AD-related plasma biomarkers (pTau217, pTau181, NfL, and GFAP) to identify shared genetic factors across these biomarkers. This approach aims to capture common biological pathways underlying multiple aspects of AD pathophysiology. The study identified genome-wide significant associations at the PPP4R2 locus.

TARGET GENE

PPP4R2, APOE

MODEL SYSTEM

human patients - East Asian cohort (K-ROAD)

ESTIMATED COST

TIMELINE

0 months

PATHWAY

protein phosphatase signaling, shared AD pathophysiology

SOURCE

extracted_from_pmid_41804841

PRIMARY OUTCOME

composite biomarker score

Scoring Dimensions

📖 Wiki Pages

APOE contributes to Alzheimer's disease by regulathypothesis APOE — Apolipoprotein Egene apoe-genotype-guided-preventiontherapeutic APOE Lipid Dysregulation Causal Chain in ADmechanism APOE Lipid Metabolism Pathway in Alzheimer's Diseamechanism APOE Genotyping for Neurodegenerative Disease Riskdiagnostic APOE contributes to Alzheimer's disease by regulathypothesis APOE - Apolipoprotein Escidex_docs APOE-Expressing Astrocytescell GFAP (Glial Fibrillary Acidic Protein) - Diagnostidiagnostic gfap-biomarker-adbiomarker GFAP (Glial Fibrillary Acidic Protein Gene)gene GFAP in Alzheimer's Diseasebiomarker GFAP-Guided Astrocyte Modulation Therapyidea GFAP (Glial Fibrillary Acidic Protein) - Biomarkerbiomarker

Protocol

Establish human patients - East Asian cohort (K-ROAD) cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for PPP4R2, APOE, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure composite biomarker score together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting PPP4R2, APOE shifts composite biomarker score in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (composite biomarker score) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)0.795

Competitive APOE4 Domain Stabilization Peptides0.784

APOE4-Specific Proteolytic Fragment Inhibition Therapy0.777

APOE4 Allosteric Rescue via Small Molecule Chaperones0.765

APOE Isoform Expression Across Glial Subtypes0.743

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.